Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

Next Previous
Trial Profile

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lifileucel (Primary) ; LN 145 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Ipilimumab; Nivolumab; Pembrolizumab
  • Indications Adenocarcinoma; Head and neck cancer; Large cell carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Iovance Biotherapeutics

Most Recent Events

  • 08 May 2025 According to an Iovance Biotherapeutics media release, Cohorts 3D and 3E in IOV-COM-202 trial are investigating this regimen to inform a registrational and confirmatory trial design in frontline advanced NSCLC.
  • 08 May 2025 According to an Iovance Biotherapeutics media release, Cohort 1D in the IOV-COM-202 trial will be investigating lifileucel in combination with nivolumab and relatlimab in frontline advanced melanoma
  • 23 Apr 2025 According to an Iovance Biotherapeutics media release, a poster on study design of phase 2 trial of lifileucel in frontline advanced non-small cell lung cancer will be presented at the 2025 ASCO Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top